Autoimmune & Chronic Inflammation Peptide Stack 2026: Thymosin Alpha-1, LL-37, KPV & BPC-157 Research Protocol

# Autoimmune & Chronic Inflammation Peptide Stack 2026: Thymosin Alpha-1, LL-37, KPV & BPC-157 Research Protocol

> Research Disclaimer: This information is for research purposes only. The compounds described are research chemicals and/or investigational drugs not approved for treating autoimmune conditions or chronic inflammation in humans outside of licensed clinical settings. This is not medical advice. Consult qualified professionals before any research use.

Overview

Autoimmune disease and chronic systemic inflammation share a core pathological feature: the immune system fails to distinguish self from non-self, or fails to terminate inflammatory responses after the triggering threat has been cleared. This dysregulation operates across multiple immune compartments — T regulatory cells, innate pattern recognition, cytokine signaling networks, and mucosal barrier integrity — making single-target interventions frequently insufficient.

This research protocol examines a four-compound stack designed to address immune dysregulation at multiple levels:

• •Thymosin Alpha-1 (Tα1) — thymic peptide that restores T regulatory cell function and immune homeostasis
• •LL-37 — cathelicidin antimicrobial peptide that bridges innate and adaptive immunity while modulating TLR signaling
• •KPV — alpha-MSH-derived tripeptide that suppresses the central NF-κB inflammatory pathway in epithelial tissue
• •BPC-157 — cytoprotective peptide that maintains mucosal barrier integrity and suppresses systemic inflammatory mediators

Each compound targets a distinct immune or inflammatory mechanism: thymic T-cell regulation (Thymosin Alpha-1), innate immune communication (LL-37), epithelial NF-κB suppression (KPV), and gut-systemic inflammatory interface (BPC-157).

Why Stack These Peptides? Mechanistic Rationale

Autoimmune and chronic inflammatory conditions are maintained by interconnected dysregulations that reinforce each other:

T regulatory cell dysfunction (targeted by Thymosin Alpha-1): In autoimmune disease, regulatory T cells (Tregs) that normally suppress autoreactive T cells fail to maintain tolerance. Tα1 restores Treg function and rebalances Th1/Th2/Th17 responses toward immune homeostasis — the foundational immunological requirement.

Innate immune dysregulation (targeted by LL-37): Pattern recognition receptor (TLR) signaling drives much of the innate immune activation in autoimmune disease, both through microbial triggers and self-derived damage-associated molecular patterns (DAMPs). LL-37 modulates TLR4/7/9 signaling in ways that reduce excessive innate activation while maintaining antimicrobial defense.

Epithelial NF-κB inflammatory amplification (targeted by KPV): In autoimmune conditions affecting mucosal tissues (IBD, celiac, lupus with gut involvement), epithelial NF-κB drives chronic cytokine amplification loops. KPV directly suppresses NF-κB in intestinal epithelial cells through PepT1-mediated intracellular delivery — breaking the local inflammatory amplification.

Gut-systemic inflammatory interface (targeted by BPC-157): Increased intestinal permeability allows bacterial products (LPS, flagellin, peptidoglycans) to enter systemic circulation, perpetuating systemic inflammatory activation. BPC-157 maintains mucosal barrier integrity, reducing this driver of chronic systemic inflammation.

These four mechanisms are non-overlapping and complementary: each addresses a different layer of immune dysregulation, from central T-cell tolerance (Tα1) to innate TLR signaling (LL-37) to epithelial cytokine amplification (KPV) to barrier-mediated systemic trigger suppression (BPC-157).

Compound Profiles

Thymosin Alpha-1 (Thymalfasin / Zadaxin)

Molecular weight: 3,108 Da

Structure: 28-amino acid N-terminally acetylated peptide

Source: Originally isolated from thymosin fraction 5 of bovine thymus

Status: Approved in 35+ countries (Zadaxin) for hepatitis B, hepatitis C, and adjunctive cancer therapy

Thymosin Alpha-1 (Tα1) is one of the most clinically validated immunomodulatory peptides in medicine, with approval in over 35 countries based on demonstrated efficacy in chronic hepatitis B and C, immune enhancement in cancer patients, and sepsis research:

T regulatory cell restoration: Tα1's primary immunological mechanism is restoration of immune homeostasis through effects on regulatory T cells (Tregs) and the Th1/Th2/Th17 balance. Research across multiple autoimmune disease models has documented Tα1-induced increases in CD4+CD25+FoxP3+ Tregs, the gold-standard marker of immunological tolerance. In autoimmune disease models (experimental autoimmune encephalomyelitis, collagen-induced arthritis, non-obese diabetic mice), Tα1 reduces disease severity by restoring Treg-mediated suppression of autoreactive effector T cells.

TLR9 and dendritic cell maturation: Tα1 signals through Toll-like receptor 9 (TLR9) on plasmacytoid dendritic cells (pDCs), driving type I interferon production. This TLR9/IFN-α axis is critical for antiviral immunity and for proper maturation of dendritic cells toward a regulatory (tolerogenic) rather than pro-inflammatory phenotype. In autoimmune contexts, tolerogenic DCs that present self-antigens in a non-inflammatory context are essential for preventing autoreactive T cell activation.

STAT1/STAT4 signaling: Tα1 promotes STAT1 phosphorylation (interferon signaling) and STAT4 activation (IL-12 signaling), driving Th1 cell differentiation. While excessive Th1 activity drives some autoimmune diseases, STAT1/STAT4-mediated immunity is critical for controlling the viral triggers that initiate many autoimmune conditions (molecular mimicry) and for maintaining appropriate immune surveillance.

Sepsis and critical illness research: Thymosin Alpha-1 has been extensively studied in sepsis research, where immune paralysis (failure to mount adequate antimicrobial responses) coexists with systemic hyperinflammation. Tα1 acts as an immunorestorer in this context, improving T cell count, function, and HLA-DR expression on monocytes in clinical studies. This "immune reset" mechanism is relevant to chronic inflammatory conditions where similar exhaustion/paralysis phenotypes develop.

Clinical data: A meta-analysis of Thymosin Alpha-1 in hepatitis B (including multiple RCTs) demonstrates significant improvement in seroconversion rates. In COVID-19 research (2020–2021), Tα1 (Zadaxin) was used in clinical trials in China with reported reductions in mortality in severe COVID-19 patients.

Research parameters: Approved dose: 1.6 mg subcutaneous twice weekly (for hepatitis indications). Research protocols for autoimmune biology vary.

See full research profile: Thymosin Alpha-1

---

LL-37 — Human Cathelicidin Antimicrobial Peptide (CAMP)

Molecular weight: 4,493.3 Da

Structure: 37 amino acids, amphipathic helix; C-terminal fragment of the hCAP-18 precursor

Gene: CAMP (cathelicidin antimicrobial peptide)

Expression: Neutrophils, epithelial cells, monocytes, NK cells, plasma

LL-37 is the only human cathelicidin, produced from the hCAP-18 precursor primarily in neutrophils and epithelial cells. It functions at the intersection of innate antimicrobial defense and adaptive immune communication:

Antimicrobial activity: LL-37 disrupts bacterial membranes through electrostatic interaction with negatively charged phospholipid headgroups, then inserts into the lipid bilayer, forming pores that kill both gram-positive and gram-negative bacteria. This broad-spectrum antimicrobial activity helps maintain the microbiome-host immune balance that chronic inflammatory conditions disrupt.

TLR4/7/9 modulation: LL-37 has complex effects on TLR signaling — acting as both an activator and an inhibitor depending on context. LL-37 can inhibit TLR4 response to LPS (by sequestering LPS before it reaches TLR4), reducing the "endotoxemia" signaling that drives systemic inflammatory activation in conditions with increased gut permeability. Conversely, LL-37 forms complexes with self-DNA and RNA that can activate TLR7/9 on plasmacytoid dendritic cells — an important mechanism in psoriasis and lupus research.

Chemokine receptor engagement: LL-37 acts as a chemokine, directly binding FPRL1 (formyl peptide receptor-like 1/FPR2) on neutrophils, monocytes, and mast cells, directing immune cell migration to sites of infection or injury. In chronic inflammatory conditions, aberrant chemokine signaling perpetuates immune cell infiltration into otherwise healthy tissue.

Wound healing and tissue repair: Beyond antimicrobial activity, LL-37 promotes wound healing through multiple mechanisms: EGFR transactivation (driving epithelial migration and proliferation), VEGF upregulation (angiogenesis), and anti-apoptotic signaling in epithelial cells. These tissue repair functions are relevant in autoimmune disease where chronic inflammation damages mucosal and connective tissues.

Immunomodulatory complementarity with Tα1: Thymosin Alpha-1 operates primarily on adaptive immunity (T cells, dendritic cell maturation), while LL-37 operates primarily on innate immunity (TLR signaling, antimicrobial defense, chemokine function). This adaptive/innate division of labor makes them mechanistically complementary in immune modulation research.

Research parameters: LL-37 research typically uses locally delivered or systemic doses ranging from 10 mcg/kg to 10 mg/kg in animal models depending on the model and indication.

See full research profile: LL-37

---

KPV — α-MSH-Derived Anti-Inflammatory Tripeptide

Molecular weight: 340.4 Da

Structure: Lys-Pro-Val

Origin: C-terminal tripeptide of alpha-melanocyte stimulating hormone (α-MSH)

Primary delivery mechanism: PepT1 (SLC15A1) oligopeptide transporter in gut epithelium

In the context of autoimmune and chronic inflammation research, KPV's relevance extends beyond gut-specific inflammation to the broader NF-κB signaling network that drives chronic inflammatory disease:

Central NF-κB pathway suppression: NF-κB is the master transcription factor for inflammatory gene expression — driving production of TNF-α, IL-1β, IL-6, IL-8, ICAM-1, and dozens of other inflammatory mediators. In autoimmune disease, chronic NF-κB activation in epithelial cells, macrophages, and lymphocytes maintains the pro-inflammatory state. KPV suppresses IκB kinase (IKK) phosphorylation, preventing NF-κB nuclear translocation from within the cell — a fundamentally different approach from surface receptor blockade.

Alpha-MSH family context: α-MSH and its receptor MC1R/MC3R engage a broader anti-inflammatory circuit through cAMP elevation and PKA-mediated suppression of NF-κB. KPV, as the C-terminal tripeptide, retains part of this mechanism while being small enough to enter cells directly via PepT1, allowing intracellular NF-κB suppression rather than receptor-level modulation.

IBD and mucosal autoimmunity: In mouse models of colitis, KPV reduces histological damage, neutrophil infiltration, and mucosal cytokine levels comparable to corticosteroids in some model systems, without the systemic immunosuppression or metabolic side effects of steroids. This makes KPV particularly relevant to mucosal autoimmunity research.

Systemic administration route: While the PepT1 mechanism makes oral KPV highly relevant for gut-specific autoimmune research, subcutaneous KPV also demonstrates systemic anti-inflammatory effects, suggesting direct suppression of NF-κB in peripheral immune cells as well.

Research parameters: Preclinical: 10 mcg/kg to 1 mg/kg; oral or subcutaneous.

See full research profile: KPV

---

BPC-157 — Gut-Systemic Inflammatory Interface

Molecular weight: 1,419.5 Da

Structure: Phe-Asp-Glu-Phe-His-Asp-Ile-Lys-His-Ala-Ile-Glu-Asp-Arg-Ser-OH

Mechanisms: VEGFR2 upregulation, growth factor modulation, NO system, FAK/paxillin pathway

In the autoimmune/chronic inflammation context, BPC-157 plays a specific role as the guardian of the mucosal barrier — preventing the gut permeability-driven systemic inflammatory amplification that perpetuates many chronic inflammatory conditions:

Gut permeability and systemic inflammation: Increased intestinal permeability — the so-called "leaky gut" phenomenon — allows bacterial lipopolysaccharide (LPS), peptidoglycans, and other microbial products to enter the systemic circulation. These endotoxins activate TLR4 on macrophages and other immune cells throughout the body, maintaining a state of low-grade systemic inflammatory activation. In autoimmune disease research, reducing gut permeability is an emerging therapeutic strategy.

BPC-157's mucosal barrier protection: Multiple research groups have documented BPC-157's ability to protect and repair the intestinal mucosal barrier in models of NSAID-induced damage, acetic acid colitis, and alcohol-induced intestinal injury. The mechanisms include upregulation of tight junction proteins, promotion of mucosal angiogenesis (ensuring adequate blood supply for barrier maintenance), and suppression of pro-inflammatory growth factor dysregulation.

Systemic anti-inflammatory effects: BPC-157 demonstrates anti-inflammatory effects beyond the gut: in models of joint inflammation (research relevant to rheumatoid arthritis), pancreatic inflammation, and systemic inflammatory conditions, BPC-157 reduces inflammatory markers through NO system modulation and suppression of TNF-α signaling.

FAK/paxillin pathway: BPC-157 activates focal adhesion kinase (FAK) signaling, which promotes cell migration and wound healing in epithelial and endothelial cells. FAK signaling also modulates NF-κB activity — providing a second point of convergence with KPV's mechanism in epithelial cells.

Research parameters: 10 ng/kg to 10 mcg/kg in animal models; oral and systemic routes both studied.

See full research profile: BPC-157

Stack Protocol

Dosing Windows & Sequencing

Twice Weekly (Thymosin Alpha-1):

• •Subcutaneous injection twice per week (Monday/Thursday, or equivalent)
• •Mimics the approved Zadaxin dosing protocol; allows for sustained but not continuous T-regulatory cell modulation
• •Tα1's effects on Tregs accumulate over weeks; the twice-weekly protocol is the established clinical research standard

Daily or Every Other Day (LL-37):

• •Subcutaneous injection daily or every other day depending on research protocol
• •LL-37's antimicrobial and immune communication effects are relevant continuously in chronic inflammatory research models
• •Some protocols use pulse dosing to avoid receptor desensitization

Twice Daily (KPV):

• •Oral KPV taken between meals (morning fasted and afternoon fasted) to maximize PepT1 transport
• •Continuous NF-κB suppression in gut epithelium requires consistent KPV levels; twice-daily oral dosing maintains this

Daily (BPC-157):

• •Subcutaneous: once or twice daily (morning and/or evening)
• •Oral BPC-157: can be taken daily in water for gut-specific mucosal effects in research protocols

Reconstitution Notes

Thymosin Alpha-1:

• •Supplied as lyophilized powder (Zadaxin: 1.6 mg vials with diluent)
• •Reconstitute with supplied sterile water (Zadaxin); for research-grade Tα1, use sterile BAC water to 0.5–2 mg/mL
• •Store reconstituted at 4°C; use within 24 hours per Zadaxin PI (some research-grade formulations stable for longer)

LL-37:

• •Reconstitute lyophilized LL-37 with sterile BAC water or saline to 0.5–5 mg/mL
• •Handle with care — LL-37 is membrane-active; avoid protein adsorption to tube surfaces
• •Store at 4°C (reconstituted); -20°C (lyophilized); avoid repeated freeze-thaw

KPV:

• •Reconstitute with sterile water for injection to 1–5 mg/mL for subcutaneous use
• •For oral use: dissolve in water (no special vehicle needed — KPV is PepT1-transported in gut)
• •Store at 4°C reconstituted; -20°C lyophilized

BPC-157:

• •Reconstitute with sterile BAC water to 0.5–1 mg/mL
• •Swirl to dissolve; store at 4°C for up to 4 weeks
• •Oral formulation: dissolve in water immediately before use

Storage Summary

Research Evidence Summary

Evidence quality across this stack is substantial:

• •Thymosin Alpha-1: The best-evidenced compound in this stack for immune modulation — approved in 35+ countries, with Phase III trial data in hepatitis, cancer adjunctive therapy, and sepsis research. The evidence for Treg restoration and immune homeostasis is extensive.

• •LL-37: Multiple published research articles on TLR modulation, antimicrobial activity, and immune communication. Human dermatology research has established LL-37's role in psoriasis and wound healing. More extensive mechanistic evidence is available than clinical trial data for autoimmune indications specifically.

• •KPV: Strong preclinical evidence in IBD models; mechanism of action (PepT1/NF-κB) is well-established by multiple research groups. Human clinical data specifically for autoimmune indications is limited.

• •BPC-157: Extensive preclinical research (30+ years); multiple independent laboratories have confirmed mucosal protective effects. Human clinical data is preliminary/limited.

No published study has examined this four-compound combination. Individual compound mechanisms are well-established; their rationale for combination in autoimmune/inflammatory research is mechanistically grounded.

Frequently Asked Questions

Q: Is Thymosin Alpha-1 the same as Thymosin Beta-4 (TB-500)?

A: No. They are structurally and mechanistically distinct peptides. Thymosin Alpha-1 is a 28-amino acid thymic immunomodulatory peptide; Thymosin Beta-4 is a 43-amino acid actin-binding peptide primarily involved in tissue repair, wound healing, and cell migration. Their functions are complementary but not overlapping. See our comparison of Thymosin Alpha-1 vs Thymosin Beta-4.

Q: Why include BPC-157 in an autoimmune stack?

A: BPC-157 addresses the gut permeability component of autoimmune disease — a growing research priority. Increased intestinal permeability allows bacterial products to drive systemic inflammatory activation, which may trigger or worsen autoimmune flares. BPC-157's mucosal protective effects make it mechanistically relevant to autoimmune research even when the primary disease manifestation is extra-intestinal.

Q: Is LL-37 safe for research use?

A: LL-37 is an endogenous human peptide expressed by neutrophils and epithelial cells. Exogenous LL-37 research uses doses that aim to replicate or modestly exceed physiological concentrations. Its membrane-active properties mean it should be handled carefully — high concentrations can be cytotoxic. Research protocols use dose ranges well below toxic thresholds established in animal safety studies.

Q: Can Thymosin Alpha-1 be used in autoimmune research models that are not hepatitis-related?

A: Yes. Thymosin Alpha-1's mechanism (Treg restoration, tolerogenic dendritic cell induction) is relevant across autoimmune conditions. It has been studied in research models of multiple sclerosis, rheumatoid arthritis, lupus, and type 1 diabetes. The approved hepatitis indications represent the most clinically validated applications; autoimmune research uses are investigational.

Q: How do KPV and BPC-157 complement each other in this stack?

A: KPV suppresses the NF-κB inflammatory signaling cascade from within intestinal epithelial cells; BPC-157 repairs the physical mucosal barrier and promotes angiogenesis for mucosal blood supply. KPV addresses the "fire" of epithelial inflammation; BPC-157 addresses the "structural damage" from that fire. They are mechanistically complementary with minimal overlap.

Where to Source These Peptides

Compare verified suppliers for each compound in this stack:

• •Compare Thymosin Alpha-1 suppliers
• •Compare LL-37 suppliers
• •Compare KPV suppliers
• •Compare BPC-157 suppliers

For research purposes only. Verify compound purity via third-party Certificate of Analysis before any research use.